Search Results - "Krepler, C"

A stress-induced early innate response causes multidrug tolerance in melanoma by Ravindran Menon, D, Das, S, Krepler, C, Vultur, A, Rinner, B, Schauer, S, Kashofer, K, Wagner, K, Zhang, G, Bonyadi Rad, E, Haass, N K, Soyer, H P, Gabrielli, B, Somasundaram, R, Hoefler, G, Herlyn, M, Schaider, H

“…Acquired drug resistance constitutes a major challenge for effective cancer therapies with melanoma being no exception. The dynamics leading to permanent…”
Get full text

MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines by Vultur, A, Villanueva, J, Krepler, C, Rajan, G, Chen, Q, Xiao, M, Li, L, Gimotty, P A, Wilson, M, Hayden, J, Keeney, F, Nathanson, K L, Herlyn, M

“…Elevated activity of the mitogen-activated protein kinase (MAPK) signaling cascade is found in the majority of human melanomas and is known to regulate…”
Get full text

A stress-induced early innate response causes multidrug tolerance in melanoma by Menon, D Ravindran, Das, S, Krepler, C, Vultur, A, Rinner, B, Schauer, S, Kashofer, K, Wagner, K, Zhang, G, Rad, E Bonyadi, Haass, N K, Soyer, H P, Gabrielli, B, Somasundaram, R, Hoefler, G, Herlyn, M, Schaider, H

“…Correction to: Oncogene (2015) 34, 4448–4459; doi:10.1038/onc.2014.372; published online 24 November 2014. In this article, published online 24 November 2014,…”
Get full text

Targeting the ATR-Chk1 axis with PARP inhibition results in tumor regression in BRCA mutant models by George, E, Kim, H, Ragland, R, Rafail, S, Zhang, R, Krepler, C, Morgan, M.A, Herlyn, M, Brown, E, Simpkins, F

Get full text

Capitalizing on synthetic lethality in homologous recombination-deficient high-grade serous ovarian cancers with a novel ATR inhibitor by George, E, Kim, H, Ragland, R, Brown, E, Butler, L, Gilad, O, Tanyi, J.L, Zhang, R, Krepler, C, Lee, R, Morgan, M.A, Burger, R.A, Ko, E.M, Kim, S.H, Herlyn, M, Simpkins, F

Get full text

93 A stress induced early innate response causes multi-drug tolerance in melanoma by Menon, D.R, Das, S, Krepler, C, Vultur, A, Rinner, B, Schauer, S, Kashofer, K, Wagner, K, Zhang, G, Rad, E. Bonyadi, Soyer, H.P, Gabrielli, B, Somasundaram, R, Hoefler, G, Herlyn, M, Schaider, H

Get full text

1116P Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting by Cowey, C.L., Boyd, M., Aguilar, K.M., Beeks, A., Krepler, C., Scherrer, E.

Get full text

Alternative splicing of IL-24 in melanocytes by deletion of exons 3 and 5 by Allen, M., Pratscher, B., Krepler, C., Frei, K., Schöfer, C., Pehamberger, H., Müller, M., Lucas, T.

“…Summary Two novel interleukin‐24 (IL‐24) splice variants were identified in normal human melanocytes by sequencing cloned polymerase chain reaction (PCR)…”
Get full text

1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma by Lee, J., Liu, X.Q., Zhao, Q., Kim, K-M., Kim, S.T., Sun, Y., Yearley, J., Choudhury, T., Webber, A., Krepler, C., Cristescu, R., Shui, I.

Get full text

LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial by Bottomley, A., Kicinski, M., Long, G.V., Mandala, M., Atkinson, V.G., Blank, C.U., Haydon, A.M., Dalle, S., Khattak, A., Carlino, M.S., Meshcheryakov, A., Sandhu, S.K., Sarda, S.S. Puig, Coens, C., Suciu, S., Grebennik, D., Krepler, C., Lorigan, P., Robert, C., Eggermont, A.M.M.

Get full text

LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 by Fernandez, A.M. Arance, O'Day, S.J., Merino, L. de la Cruz, Petrella, T., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez-Rodas, I., Spreafico, A., Victoria Atkinson, V., Costa Svedman, F., Smith, A.D., Chen, K., Diede, S.J., Krepler, C., Long, G.V.

Get full text

LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial by Eggermont, A.M.M., Blank, C.U., Mandala', M., Long, G.V., Atkinson, V., Dalle, S., Haydon, A.M., Meshcheryakov, A., Khattak, A., Carlino, M., Sandhu, S., Sarda, S. Puig, Ascierto, P.A., van Akkooi, A.C.J., Krepler, C., Ibrahim, N., Marreaud, S.I., Kicinski, M., Suciu, S., Robert, C.

Get full text

76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials by Luke, J.J., Long, G.V., Robert, C., Carlino, M.S., Choueiri, T.K., Haas, N.B., O'Brien, M.E.R., Paz-Ares, L., Peters, S., Powles, T.B., Leiby, M.A., Lin, J., Zhao, Y., Krepler, C., Perini, R.F., Pietanza, M.C., Samkari, A., Gruber, T., Ibrahim, N., Eggermont, A.M.M.

Get full text

Erratum: A stress-induced early innate response causes multidrug tolerance in melanoma by Menon, D Ravindran, Das, S, Krepler, C, Vultur, A, Rinner, B, Schauer, S, Kashofer, K, Wagner, K, Zhang, G, Rad, E Bonyadi, Haass, N K, Soyer, H P, Gabrielli, B, Somasundaram, R, Hoefler, G, Herlyn, M, Schaider, H

“…Correction to: Oncogene advance online publication, 24 November 2014; doi:10.1038/onc.2014.372 In this article, published online 24 November 2014, the authors…”
Get full text

InterPATH-001 trial in progress: Adjuvant V940 (mRNA-4157) with pembrolizumab versus placebo in patients with high-risk stage II-IV melanoma by Weber, J.S., Luke, J.J., Carlino, M.S., Khattak, M.A., Meehan, R., Brown, M., Zhang, J., Krepler, C., Duic, J.P., Long, G.V.

Get full text

A-458 - InterPATH-001 trial in progress: Adjuvant V940 (mRNA-4157) with pembrolizumab versus placebo in patients with high-risk stage II-IV melanoma by Weber, J.S., Luke, J.J., Carlino, M.S., Khattak, M.A., Meehan, R., Brown, M., Zhang, J., Krepler, C., Duic, J.P., Long, G.V.

Get full text

Pegylated and Conventional Interferon-α Induce Comparable Transcriptional Responses and Inhibition of Tumor Growth in a Human Melanoma SCID Mouse Xenotransplantation Model by Krepler, Clemens, Certa, Ulrich, Wacheck, Volker, Jansen, Burkhard, Wolff, Klaus, Pehamberger, Hubert

“…Interferon-alpha (IFN-α) is widely used for the treatment of viral infections and primary cancers. In the present study, we investigated whether the…”
Get full text

Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma by ALLEN, Matthew, PRATSCHER, Barbara, ROKA, Florian, KREPLER, Clemens, WACHECK, Volker, SCHÖFER, Christian, PEHAMBERGER, Hubert, MÜLLER, Markus, LUCAS, Trevor

“…Expression of melanoma differentiation associated gene-7 (mda-7) also known as interleukin 24 (IL-24) decreases during melanoma cell differentiation and…”
Get full text

CpG Oligonucleotides Elicit Antitumor Responses in a Human Melanoma NOD/SCID Xenotransplantation Model by Krepler, Clemens, Wacheck, Volker, Strommer, Sabine, Hartmann, Gunther, Polterauer, Peter, Wolff, Klaus, Pehamberger, Hubert, Jansen, Burkhard

“…For patients with advanced malignant melanoma, the 5 y survival rate with current treatment modalities is low. There is an urgent need for more effective…”
Get full text

Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice by Wacheck, Volker, Krepler, Clemens, Strommer, Sabine, Heere-Ress, Elisabeth, Klem, Robert, Pehamberger, Hubert, Eichler, Hans-Georg, Jansen, Burkhard

“…The Bcl-2 antisense oligonucleotide (AS-ODN) G3139 chemosensitizes human malignancies by downregulating the antiapoptotic protein Bcl-2. Because G3139 contains…”
Get more information